Bicycle Therapeutics plc (NASDAQ:BCYC - Free Report) - Stock analysts at B. Riley dropped their FY2025 earnings per share (EPS) estimates for shares of Bicycle Therapeutics in a research report issued to clients and investors on Monday, March 3rd. B. Riley analyst K. Patel now expects that the company will post earnings of ($3.75) per share for the year, down from their previous forecast of ($3.70). B. Riley has a "Neutral" rating and a $17.00 price objective on the stock. The consensus estimate for Bicycle Therapeutics' current full-year earnings is ($3.06) per share. B. Riley also issued estimates for Bicycle Therapeutics' Q4 2025 earnings at ($1.01) EPS, FY2026 earnings at ($4.34) EPS, FY2027 earnings at ($4.38) EPS and FY2028 earnings at ($3.92) EPS.
A number of other equities analysts have also recently weighed in on the company. JMP Securities decreased their price target on Bicycle Therapeutics from $32.00 to $26.00 and set a "market outperform" rating for the company in a report on Wednesday, December 18th. Needham & Company LLC restated a "buy" rating and set a $30.00 price objective on shares of Bicycle Therapeutics in a research note on Wednesday, February 26th. Stephens restated an "equal weight" rating and set a $15.00 price objective on shares of Bicycle Therapeutics in a research note on Wednesday, January 22nd. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $33.00 target price on shares of Bicycle Therapeutics in a research report on Wednesday, February 26th. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $29.14.
Get Our Latest Analysis on Bicycle Therapeutics
Bicycle Therapeutics Stock Performance
Shares of NASDAQ:BCYC traded down $0.42 during trading on Wednesday, reaching $10.23. 243,763 shares of the stock were exchanged, compared to its average volume of 298,858. The firm's 50-day moving average price is $12.77 and its 200 day moving average price is $18.89. The firm has a market cap of $706.34 million, a price-to-earnings ratio of -3.11 and a beta of 1.12. Bicycle Therapeutics has a 12-month low of $9.99 and a 12-month high of $28.67.
Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last issued its earnings results on Tuesday, February 25th. The company reported ($0.75) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.85) by $0.10. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. The business had revenue of $3.70 million during the quarter, compared to analysts' expectations of $5.47 million. During the same quarter in the previous year, the business earned ($1.16) EPS. The company's revenue for the quarter was down 30.2% on a year-over-year basis.
Institutional Investors Weigh In On Bicycle Therapeutics
Institutional investors have recently bought and sold shares of the business. Assetmark Inc. purchased a new stake in shares of Bicycle Therapeutics during the 3rd quarter worth about $34,000. Barclays PLC boosted its stake in Bicycle Therapeutics by 878.3% in the 4th quarter. Barclays PLC now owns 2,612 shares of the company's stock valued at $37,000 after buying an additional 2,345 shares in the last quarter. Avior Wealth Management LLC acquired a new stake in Bicycle Therapeutics in the 4th quarter valued at $57,000. China Universal Asset Management Co. Ltd. raised its position in Bicycle Therapeutics by 30.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 9,329 shares of the company's stock valued at $131,000 after purchasing an additional 2,191 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its position in shares of Bicycle Therapeutics by 26.8% during the third quarter. JPMorgan Chase & Co. now owns 8,424 shares of the company's stock worth $191,000 after acquiring an additional 1,782 shares during the last quarter. 86.15% of the stock is currently owned by institutional investors and hedge funds.
Insider Activity at Bicycle Therapeutics
In related news, CAO Travis Alvin Thompson sold 2,686 shares of the stock in a transaction on Monday, January 6th. The stock was sold at an average price of $15.00, for a total value of $40,290.00. Following the completion of the transaction, the chief accounting officer now owns 32,146 shares in the company, valued at $482,190. This trade represents a 7.71 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Bros. Advisors Lp Baker acquired 985,397 shares of the firm's stock in a transaction on Friday, December 13th. The shares were acquired at an average price of $13.76 per share, with a total value of $13,559,062.72. Following the completion of the transaction, the director now directly owns 9,537,643 shares in the company, valued at approximately $131,237,967.68. This trade represents a 11.52 % increase in their position. The disclosure for this purchase can be found here. Insiders sold 27,677 shares of company stock valued at $392,413 over the last 90 days. 8.50% of the stock is currently owned by corporate insiders.
Bicycle Therapeutics Company Profile
(
Get Free Report)
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.
Further Reading

Before you consider Bicycle Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bicycle Therapeutics wasn't on the list.
While Bicycle Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.